Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Oral Obesity Frontie | Structure Therapeutics leads in developing oral small molecule treatments for obesity and diabetes, with promising candidates ACCG-2671 and orforglipron in the pipeline. |
Clinical Milestones | Explore the potential game-changing results expected from orforglipron's Phase 3 trials and ACCG-2671's entry into Phase 1 testing, shaping the future of obesity treatment. |
Market Dynamics | Delve into Structure Therapeutics' position in the competitive landscape of obesity and diabetes treatments, balancing innovation against established pharmaceutical giants. |
Financial Outlook | Analyst targets range from $37.50 to $120, with an average upside potential of 219%. The company's performance hinges on upcoming clinical trial outcomes. |
Metrics to compare | GPCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGPCRPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.1x | −0.3x | −0.5x | |
PEG Ratio | 0.57 | 0.00 | 0.00 | |
Price/Book | 1.2x | 2.2x | 2.6x | |
Price / LTM Sales | - | 1.9x | 3.3x | |
Upside (Analyst Target) | 326.4% | 173.2% | 45.4% | |
Fair Value Upside | Unlock | 19.7% | 7.7% | Unlock |